Sign In
14 Mar 2025 07:00
14 March 2025
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Block Listing Return
Name of applicant: | Oncimmune Holdings plc | |||
Name of scheme: | Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans | |||
Period of return: | From: | 12/02/25 | To: | 13/03/25 |
Balance of unallotted securities under scheme(s) from previous return: | 5,678,464 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
Less: Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 0 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,678,464 | |||
For further information:
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Ondraya Swanson (Corporate Broking)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
For more information, visit www.oncimmune.com
Follow the stocks
